What is Selank?

Selank is a synthetic peptide analog of tuftsin extended with a Pro-Gly-Pro sequence. It is best known from Russian neuropeptide literature for anxiety, mood, and cognition-adjacent research. [1][2][3]

Its identity is immune-neuropeptide hybrid: tuftsin biology gives the immune-signaling origin, while the marketed use case is usually intranasal anxiolytic or stress support. [1][2][3]

Selank needs separation from Semax. They are often paired, but they have different sequences, target stories, and practical intent. [1][2][3]

What Selank is investigated for

Selank evidence is grouped by practical use case and intranasal route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

Anxiety reduction without sedation

Intranasal

55% Emerging

Anxiety reduction has Selank’s most direct human-facing evidence, but not a large international approval program. [1][2][6]

Human evidence

A human generalized-anxiety and neurasthenia publication supports Selank as an anxiolytic candidate, with regional and study-quality limits. [1][2][6]

Animal / mechanistic evidence

Tuftsin-analog reviews and adaptive-behavior studies support anxiolytic mechanism plausibility. [1][2][6]

Immune modulation

Intranasal

52% Emerging

Immune modulation is distinct from Selank anxiolytic claims and depends on limited human and mechanistic evidence. [3][8][2]

Human evidence

A human anxiety-asthenic-disorder study reported immunomodulatory effects of Selank. [3][8][2]

Animal / mechanistic evidence

Gene-expression studies report changes in chemokine, cytokine, and receptor expression after Selank and its fragments. [3][8][2]

Stress resilience

Intranasal

42% Preliminary

Stress resilience is plausible but less clinically developed than anxiety reduction. [6][7][2]

Human evidence

Direct modern human stress-resilience trials are not established in the cited literature. [6][7][2]

Animal / mechanistic evidence

Adaptive-behavior and tuftsin-analog studies support a stress-response rationale. [6][7][2]

Cognitive support during stress

Intranasal

34% Limited

Cognitive support should be framed around stress models, not as broad nootropic proof. [4][6][5]

Human evidence

Direct human cognitive-enhancement outcomes for Selank are not established in the cited literature. [4][6][5]

Animal / mechanistic evidence

Rat memory-impairment and stress-behavior publications support cognition discussion only in stress or impairment contexts. [4][6][5]

Evidence snapshot

Overall confidence

Emerging

55%

Selank has limited-human support for intranasal anxiolytic and stress-response use, mostly from regional literature. Cognition and sleep uses remain secondary. [1][2][3][4]

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

55%

Human evidence

Emerging

Regional clinical literature supports anxiolytic interest, but major-market approval evidence is absent. [1][2][3][4]

34%

Animal / preclinical

Limited

Mechanistic work supports stress, immune, and neurotransmitter plausibility. [1][2][3][4]

55%

Mechanism support

Emerging

Selank is discussed around GABAergic, monoamine, immune, and stress-response biology. The mechanism suggests anxiety-signal modulation without classic benzodiazepine sedation. [1][2][3][4]

Forms & administration

Selank is tracked as an intranasal stress-regulation peptide. Spray-style use is separate from injectable dosing and from Semax combinations. [10][1][2]

Nasal spray

Dosing & protocols

The notes below separate published trial design from commonly discussed cosmetic or compounded-use patterns. They are educational context only, not a prescription or product instruction.

Typical Range

Common intranasal protocols usually use 250-400 mcg per day. [10][1][2]

Frequency

Common intranasal schedules use 1-2 sessions daily. [10][1][2]

Timing Considerations

Afternoon or evening timing is the common anchor when calm focus or sleep-friendly anxiety reduction is the goal. [10][1][2]

Cycle Length

Common intranasal blocks run 2-6 weeks before changing dose or combining with Semax. [10][1][2]

What to expect

First few days

Intranasal Selank may feel like calmer focus, easier stress recovery, steadier mood, or smoother sleep transition. [1][2][3][4][10]

Weeks 2-4

Intranasal stress-regulation effects may appear as calmer anxiety frequency, steadier mood, smoother sleep continuity, or easier stress recovery. [1][2][3][4][10]

After stopping

Stress and anxiety patterns may drift back toward baseline routines after intranasal Selank use ends. [1][2][3][4][10]

Safety profile

Selank safety is mainly intranasal and neuroactive: nasal irritation, fatigue, headache, sedative overlap, and psychiatric context matter. [1][2][3][4]

Common side effects

Nasal irritation [1][2][3][4]
Fatigue [1][2][3][4]
Headache [1][2][3][4]

Cautions

Sedatives / anxiolytics [1][2][3][4]
Psychiatric medications [1][2][3][4]
Formulation variability [1][2][3][4]

What we don't know

Long-term intranasal use, medication interactions, pregnancy, and pediatric safety remain poorly characterized in major-market sources. [1][2][3][4]

Who Selank is not for

Route-specific avoid and medical-review notes:

Pregnancy or breastfeeding
Pregnancy or breastfeeding warrants medical review or avoidance for Selank. [1][2][3][4]
Unstable psychiatric symptoms
Unstable psychiatric symptoms warrants medical review or avoidance for Selank. [1][2][3][4]
Use with sedatives or anxiolytics without clinician review
Use with sedatives or anxiolytics without clinician review warrants medical review or avoidance for Selank. [1][2][3][4]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Theoretical interactions

Sedatives / anxiolytics / alcohol
Benzodiazepines, alcohol, sleep aids, or sedating supplements can compound calming effects or reduce alertness; this is a theoretical neuroactive caution. [1][2][3][4]
Psychiatric medications
SSRIs, SNRIs, antipsychotics, or mood stabilizers can make anxiety, mood, or sleep changes harder to attribute; this is a theoretical neuroactive caution. [1][2][3][4]
Other nasal sprays
Decongestant, steroid, or irritating nasal sprays can add local irritation or change intranasal tolerability; this is a route-specific caution. [1][2][3][4]

Pairing notes

Commonly included in these stacks

Semax / Selank

Semax / Selank is a two-neuropeptide stack built around focus, cognitive stress response, and anxiety-oriented support. Semax supplies the ACTH-fragment cognitive and neuroprotective rationale, while Selank supplies the tuftsin-analog anxiolytic and stress-resilience rationale.

SemaxSelank

Regulatory status

United States

In the U.S. as of 2026-06-21, Selank is not FDA-approved for the reviewed intranasal route. FDA compounding safety-risk materials flag this substance or close naming variant, so the 503A row should be read as a safety-risk bucket, not approval. [16][10][11][14][15]

Route	FDA drug approval	503A compounding
Intranasal	Not Approved Selank is not FDA-approved as an intranasal drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval. [10][11][14][15]	Flagged FDA safety-risk materials flag selank acetate for immunogenicity, aggregation, peptide impurities, and missing human safety information. This is a 503A compounding safety-risk bucket, not FDA drug approval. [16][10][11][14][15]

Intranasal

FDA drug approval

Not Approved

Selank is not FDA-approved as an intranasal drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval. [10][11][14][15]

503A compounding

Flagged

FDA safety-risk materials flag selank acetate for immunogenicity, aggregation, peptide impurities, and missing human safety information. This is a 503A compounding safety-risk bucket, not FDA drug approval. [16][10][11][14][15]

International

EU/Europe, UK, Canada, and Australia require product-specific checks in EMA/MHRA, Health Canada, and TGA registers. Research-market, supplement, or compounded availability should not be treated as therapeutic approval in those markets. [17][18][19][20]

Sports & competition

WADA S0 can apply to non-approved pharmacological substances that are not otherwise named. Tested athletes should not treat Selank intranasal route as athlete-cleared without sport-specific review. [12][10][11][14][15]

How it works

Selank is a tuftsin-derived peptide discussed around GABAergic tone, monoamine signaling, immune modulation, and stress-response biology. In plain terms, the proposed mechanism is anxiety-signal regulation without the same direct sedative pathway as benzodiazepines. [1][2][3][4]

Intranasal delivery is part of the mechanism interpretation because nasal formulation and central exposure determine whether the peptide reaches the relevant signaling environment. Psychiatric history, concurrent medications, and limited route-matched outcomes keep mood claims narrower than the mechanism story. That keeps the section anchored to biology rather than broad anxiolytic certainty. [1][2][3][4]

Research gaps & open questions

What the current literature has not yet settled about Selank:

A key evidence gap is major-market randomized anxiety trials. [1][2][3][4]

A key evidence gap is medication-interaction data. [1][2][3][4]

A key evidence gap is combination-level Semax/Selank safety. [1][2][3][4]

Common questions

Is Selank FDA-approved in the United States?

No. Selank is not FDA-approved in the U.S. for intranasal drug use, and FDA lists selank acetate with compounding safety concerns. [10][11][1][2][16][14]

Is Selank a benzodiazepine?

No. Selank is a tuftsin-derived peptide, not a benzodiazepine, but mood-medication interactions still matter. [10][11][1][2]

Is the Semax/Selank stack proven?

No. The pairing is common in peptide forums, but intranasal combination efficacy, safety, and dosing have not been established. [10][11][1][2]

Myths & misconceptions

Myth

Non-sedating claims mean there is no mood risk.

Reality

Any neuroactive compound can still affect anxiety, sleep, activation, or medication response. [1][2][3][4]

Myth

Selank is basically Semax.

Reality

They are different peptides with different intent and mechanism stories. [1][2][3][4]

History & discovery

Selank was developed from tuftsin-related peptide biology and regional anxiolytic research. Its origin story connects immune peptide design with neuropsychotropic claims, rather than classic sedative drug development. That distinction keeps the origin story tied to evidence strength, route, and product identity rather than broad clinical certainty. [1][2][3][4]

Human anxiety and neurasthenia studies positioned Selank as a peptide anxiolytic with possible mechanisms beyond benzodiazepine sedation. That shaped its stress-regulation identity. [1][2][3][4]

Reviews and animal studies tied Selank to tuftsin analogy, immune signaling, memory, and BDNF-related pathways. These milestones widened the story but did not validate combination stacks. [1][2][3][4]

Published research 12 studies

[1]

[Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia].

Zh Nevrol Psikhiatr Im S S Korsakova, 2008. human clinical.

[2]

Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity.

Protein Pept Lett, 2018. review.

[3]

[Immunomodulatory effects of selank in patients with anxiety-asthenic disorders].

Zh Nevrol Psikhiatr Im S S Korsakova, 2008. human clinical.

[4]

Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats.

Bull Exp Biol Med, 2019 Sep. animal.

[5]

[Effects of heptapeptide selank on genetically-based and situation-provoked symptoms of depression in behavior in WAG/Rij and Wistar rats, and in BALB/c mice].

Zh Vyssh Nerv Deiat Im I P Pavlova, 2008 Mar-Apr. animal.

[6]

Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress.

Neurosci Behav Physiol, 2003 Nov. animal.

[7]

Influence of long-term treatment with tuftsin analogue TP-7 on the anxiety-phobic states and body weight.

Pharmacol Rep, 2006 Jul-Aug. human clinical.

[8]

[Changes in expression of the genes for chemokines, cytokines, and their receptors in response to selank and its fragments].

Genetika, 2011 May. in vitro.

[9]

[The characteristics of the anxiolytic action of taftsin and its analog TP-7 on behavior and serotonin metabolism in the brain of rats with chronic deprivation of serotoninergic system activity].

Eksp Klin Farmakol, 1995 Nov-Dec. animal.

[10]

Drugs@FDA/openFDA query for Selank

U.S. Food and Drug Administration. database query.

[11]

Compounding and the FDA: Questions and Answers

U.S. Food and Drug Administration. official guidance.

[12]

The 2026 List of Prohibited Substances and Methods

World Anti-Doping Agency. regulatory.